ClinicalTrials.gg
CompletedNCT01267201Updated Jun 28, 2012Results posted

A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form

A Phase 1 interventional study of methylprednisolone and methylprednisolone in Biological Availability, sponsored by Pfizer. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-28.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

A new formulation of methylprednisolone is being developed. A study is needed to determine the drug availability using the new formulation, a powder for reconstitution into a suspension, versus the current commercially available tablet formulation in healthy volunteers.

02

Conditions studied

  • Biological Availability

Keywords

  • Single dose bioavailability study of methylprednisolone powder for oral suspension (4mg/mL) versus methylprednisolone tablet (32 mg)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 17.5 to 30.5 kg/m2;
  • a total body weight >45 kg (99 lbs).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease;
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    POS formulation #1

    Drug: methylprednisolone

  • Experimental
    POS formulation #2

    Drug: methylprednisolone

  • Active comparator
    commercial tablet

    Drug: methylprednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hours (hrs) post-dose

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose

  2. Plasma Decay Half-life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose

07

Results

Posted Jun 28, 2012

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneMethylprednisolone 32 mg Tablet, Formulation 1, Formulation 2Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2Methylprednisolone Formulation 1, Formulation 2, 32 mg TabletMethylprednisolone Formulation 2, 32 mg Tablet, Formulation 1Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet
Started444444
Completed344444
Not completed100000
Withdrew: Withdrawal by subject100000
Washout Period (At Least 2 Days)
Participant flow — Washout Period (At Least 2 Days)
MilestoneMethylprednisolone 32 mg Tablet, Formulation 1, Formulation 2Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2Methylprednisolone Formulation 1, Formulation 2, 32 mg TabletMethylprednisolone Formulation 2, 32 mg Tablet, Formulation 1Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet
Started344444
Completed344444
Not completed000000
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneMethylprednisolone 32 mg Tablet, Formulation 1, Formulation 2Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2Methylprednisolone Formulation 1, Formulation 2, 32 mg TabletMethylprednisolone Formulation 2, 32 mg Tablet, Formulation 1Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet
Started344444
Completed334444
Not completed010000
Withdrew: Withdrawal by subject010000
Washout Period (At Least 2 Days)
Participant flow — Washout Period (At Least 2 Days)
MilestoneMethylprednisolone 32 mg Tablet, Formulation 1, Formulation 2Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2Methylprednisolone Formulation 1, Formulation 2, 32 mg TabletMethylprednisolone Formulation 2, 32 mg Tablet, Formulation 1Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet
Started334444
Completed334444
Not completed000000
Third Intervention Period
Participant flow — Third Intervention Period
MilestoneMethylprednisolone 32 mg Tablet, Formulation 1, Formulation 2Methylprednisolone 32 mg Tablet, Formulation 2, Formulation 1Methylprednisolone Formulation 1, 32 mg Tablet, Formulation 2Methylprednisolone Formulation 1, Formulation 2, 32 mg TabletMethylprednisolone Formulation 2, 32 mg Tablet, Formulation 1Methylprednisolone Formulation 2, Formulation 1, 32 mg Tablet
Started334444
Completed334444
Not completed000000

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hours (hrs) post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
ng*hr/mLMethylprednisolone 32 mg TabletMethylprednisolone 32 mg Micronized APIMethylprednisolone 32 mg Sieve Cut API
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]1286.00 ± 385.271204.00 ± 394.651180.00 ± 355.26
Statistical analysis
  • Methylprednisolone 32 mg Tablet vs Methylprednisolone 32 mg Micronized API · Ratio of adjusted geometric means: 92.11 · 90% CI 88.23 to 96.15
  • Methylprednisolone 32 mg Tablet vs Methylprednisolone 32 mg Sieve Cut API · Ratio of adjusted geometric means: 90.22 · 90% CI 86.49 to 94.11
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLMethylprednisolone 32 mg TabletMethylprednisolone 32 mg Micronized APIMethylprednisolone 32 mg Sieve Cut API
Maximum Observed Plasma Concentration (Cmax)289.00 ± 60.42279.10 ± 82.91246.20 ± 66.05
Statistical analysis
  • Methylprednisolone 32 mg Tablet vs Methylprednisolone 32 mg Micronized API · Ratio of adjusted geometric means: 94.76 · 90% CI 88.06 to 101.98
  • Methylprednisolone 32 mg Tablet vs Methylprednisolone 32 mg Sieve Cut API · Ratio of adjusted geometric means: 83.89 · 90% CI 78.06 to 90.17
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrMethylprednisolone 32 mg TabletMethylprednisolone 32 mg Micronized APIMethylprednisolone 32 mg Sieve Cut API
Time to Reach Maximum Observed Plasma Concentration (Tmax)2.00 (1.00 to 4.00)1.00 (0.50 to 4.00)2.00 (1.00 to 3.00)
SecondaryPlasma Decay Half-life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 12, 16 and 24 hrs post-dose
Reported as:
Mean · hr
Plasma Decay Half-life (t1/2)
hrMethylprednisolone 32 mg TabletMethylprednisolone 32 mg Micronized APIMethylprednisolone 32 mg Sieve Cut API
Plasma Decay Half-life (t1/2)2.43 ± 0.392.42 ± 0.372.45 ± 0.35

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Methylprednisolone 32 mg Tablet—0/24 (0%)4/24 (16.7%)
Methylprednisolone 32 mg Micronized API—0/22 (0%)0/22 (0%)
Methylprednisolone 32 mg Sieve Cut API—0/23 (0%)1/23 (4.3%)
Most frequent other events
Most frequent other events
EventMethylprednisolone 32 mg TabletMethylprednisolone 32 mg Micronized APIMethylprednisolone 32 mg Sieve Cut API
HeadacheNervous system disorders3/240/220/23
PhlebitisVascular disorders0/240/221/23
Gastrooesophageal reflux diseaseGastrointestinal disorders1/240/220/23
Pain in extremityMusculoskeletal and connective tissue disorders1/240/220/23
ParaesthesiaNervous system disorders1/240/220/23

Baseline characteristics

Age Continuous
Age Continuous(Years)Entire Study Population
Mean32.5 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female2
Male22
08

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2010
First posted
Dec 28, 2010
Start
Nov 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Jun 28, 2012
Last update
Jun 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01267201
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 28, 2010
Start date
Nov 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Jun 28, 2012
Last update
Jun 28, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone

Start the discussion